Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-3373 in advanced solid tumours
NCT02723240Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jan 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosifloxuridine nafalbenamide in solid tumor (2 arms), sponsored by University of Oxford. Primary endpoint: Recommended Phase 2 Dose. Started Jan 2016; status: completed.
02
Drugs
fosifloxuridine nafalbenamide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02723240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723240.